A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Summary

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.

Timeline

Start

2025-07-07

Primary completion

2027-01-28

Completion

2027-03-01

Drugs

Indications